Stay updated on Anti-PD1 Brain Collaboration Clinical Trial
Sign up to get notified when there's something new on the Anti-PD1 Brain Collaboration Clinical Trial page.

Latest updates to the Anti-PD1 Brain Collaboration Clinical Trial page
- Check4 days agoChange DetectedThe page now includes an expanded Locations section listing New South Wales, Queensland, South Australia, and Victoria, along with updated metadata (Last Update Posted (Estimated) and Revision: v3.3.3). Older state-specific headings and the previous revision number were removed.SummaryDifference0.6%

- Check11 days agoChange DetectedAdded a new site in Wollstonecraft, New South Wales, Australia (2065). The dosing schedule was updated to allow nivolumab 480 mg every 4 weeks after 52 weeks, and the study completion window was extended to up to 10 years, with expanded biomarker plans (PD-L1 status, immune markers) and scheduled blood/tissue sampling.SummaryDifference0.6%

- Check19 days agoNo Change Detected
- Check25 days agoChange DetectedPublications section now notes that items are automatically filled from PubMed, and the revision tag was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check33 days agoChange DetectedA site-wide government funding/operating status notice has been removed from the page. The study details, eligibility criteria, and other core trial information remain unchanged.SummaryDifference0.4%

- Check40 days agoChange DetectedMelanoma Institute Australia has been removed, along with the 2017 ASCO Annual Meeting Abstract and several auxiliary link and document sections.SummaryDifference0.2%

- Check55 days agoChange DetectedNo significant changes to core study content were detected; the pages appear to show the same sections with only minor formatting adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Anti-PD1 Brain Collaboration Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anti-PD1 Brain Collaboration Clinical Trial page.